CN106994131A - A kind of application for adjusting lipid metaboli and fat compound PAQG in pharmacy - Google Patents
A kind of application for adjusting lipid metaboli and fat compound PAQG in pharmacy Download PDFInfo
- Publication number
- CN106994131A CN106994131A CN201710265740.1A CN201710265740A CN106994131A CN 106994131 A CN106994131 A CN 106994131A CN 201710265740 A CN201710265740 A CN 201710265740A CN 106994131 A CN106994131 A CN 106994131A
- Authority
- CN
- China
- Prior art keywords
- fat
- paqg
- compound
- ebp
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 23
- 150000001875 compounds Chemical class 0.000 title claims description 53
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 36
- 230000004069 differentiation Effects 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 23
- 230000014509 gene expression Effects 0.000 claims abstract description 23
- 238000009825 accumulation Methods 0.000 claims abstract description 13
- 239000002253 acid Substances 0.000 claims abstract description 12
- 230000003647 oxidation Effects 0.000 claims abstract description 12
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 12
- 102000011690 Adiponectin Human genes 0.000 claims abstract description 11
- 108010076365 Adiponectin Proteins 0.000 claims abstract description 11
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 claims abstract description 10
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 claims abstract description 10
- 102100034798 CCAAT/enhancer-binding protein beta Human genes 0.000 claims abstract description 10
- 101710134031 CCAAT/enhancer-binding protein beta Proteins 0.000 claims abstract description 10
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 claims abstract description 10
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 claims abstract description 10
- 102000000536 PPAR gamma Human genes 0.000 claims abstract description 10
- 108010016731 PPAR gamma Proteins 0.000 claims abstract description 10
- 102000040945 Transcription factor Human genes 0.000 claims abstract description 10
- 108091023040 Transcription factor Proteins 0.000 claims abstract description 10
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 10
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 10
- 230000002596 correlated effect Effects 0.000 claims abstract description 9
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 8
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 8
- 208000008589 Obesity Diseases 0.000 claims abstract description 7
- 230000036541 health Effects 0.000 claims abstract description 7
- 235000020824 obesity Nutrition 0.000 claims abstract description 7
- 230000001737 promoting effect Effects 0.000 claims abstract description 4
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 5
- 230000033228 biological regulation Effects 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000003579 anti-obesity Effects 0.000 claims description 2
- 230000003750 conditioning effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 abstract description 21
- 210000004027 cell Anatomy 0.000 abstract description 15
- 241000218978 Populus deltoides Species 0.000 abstract description 5
- -1 oleanolic acid compound Chemical class 0.000 abstract description 5
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 abstract description 3
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 abstract description 3
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 abstract description 3
- 229940100243 oleanolic acid Drugs 0.000 abstract description 3
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 2
- 208000016097 disease of metabolism Diseases 0.000 abstract description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 abstract 1
- SKKCWALCJXDUKO-UHFFFAOYSA-N Pyrocincholic acid Natural products CC1(C)CCC2(CCC3=C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1)C(=O)O SKKCWALCJXDUKO-UHFFFAOYSA-N 0.000 abstract 1
- 235000013376 functional food Nutrition 0.000 abstract 1
- 150000008505 β-D-glucopyranosides Chemical class 0.000 abstract 1
- CESLMJOIHBNCGO-UHFFFAOYSA-N pyrocincholic acid 3beta-O-beta-D-quinovopyranosyl-28-O-beta-D-glucopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1C(C)(C)C(CCC2(C)C3=C(C4CC(C)(C)CCC4(CC3)C(=O)OC3C(C(O)C(O)C(CO)O3)O)CCC32)C3(C)CC1 CESLMJOIHBNCGO-UHFFFAOYSA-N 0.000 description 69
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- 239000003925 fat Substances 0.000 description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 30
- 102100038074 5'-AMP-activated protein kinase subunit beta-1 Human genes 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 18
- 238000012545 processing Methods 0.000 description 14
- 235000011187 glycerol Nutrition 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000006698 induction Effects 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 238000010832 independent-sample T-test Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 101000833892 Homo sapiens Peroxisomal acyl-coenzyme A oxidase 1 Proteins 0.000 description 4
- 101100041816 Homo sapiens SCD gene Proteins 0.000 description 4
- 101000734339 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Proteins 0.000 description 4
- 102100026798 Peroxisomal acyl-coenzyme A oxidase 1 Human genes 0.000 description 4
- 101150097713 SCD1 gene Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 4
- 102100034825 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Human genes 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 239000012752 auxiliary agent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 101710153593 Albumin A Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000013139 quantization Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101000963424 Homo sapiens Acetyl-CoA carboxylase 1 Proteins 0.000 description 1
- 240000002717 Metadina trichotoma Species 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000011497 sour milk drink Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The New function that a kind of O β D glucopyranoside (PAQG) of 3 β O β D quinovopyranosyl of drop oleanolic acid compound Pyrocincholic Acid 28 for being extracted from yellow Populus deltoides regulate and control lipid metaboli in 3T3 L1 cells, and its application in the medicine, food and the health products that improve fat and fat correlated metabolism diseases are prepared are provided.PAQG suppresses the differentiation of 3T3 L1 PECTORAL LIMB SKELETONs by activating AMPK, lowers the expression and the release of adiponectin of differentiation associated transcription factor and albumen (PPAR γ, C/EBP β, C/EBP α and FABP4).Meanwhile, also by suppressing aliphatic acid synthesis and promoting lipid oxidation to suppress the accumulation of fat in 3T3 L1 mature fat cells.Under safely and effectively dosage, PAQG improves obesity in terms of adipocyte count and fat content size two, available for medicine, health products and the functional food for preparing the metabolic disease that preventing and treating is fat and obesity is related.
Description
Technical field：
The invention belongs to technical field of pharmaceuticals, and in particular to one kind drop oleanolic acid compound Pyrocincholic Acid
3 β-O- β-D-quinovopyranosyl-28-O- β-D-glucopyranoside (PAQG) regulate and control fat in 3T3-L1 cells
The New function of metabolism, and it is in the medicine, food and the health products that improve fat and fat correlated metabolism diseases are prepared
Using.
Technical background：
Diabetes seriously jeopardize the healthy of the mankind as a kind of chronic metabolic disease, its complication.Especially
Be the diabetes B closely related with human life style research it is also more and more.Research shows that 50% obese people is all
With diabetes B, and the fat illness rate that can make diabetes B increases by 3 times.So, the fat research with diabetes
Also increasingly receive much concern.
Obesity is clearly defined as " excessive or abnormal accumulation of fat in vivo " by the World Health Organization (WHO), and causes body
From the aspect of the content two that the reason for interior accumulation of fat can be fatty from adipocyte count and fat cell.To accumulation of fat
Research also turn into one treatment diabetes novel targets.Although there is the fat medicine of various improvement on the market,
Mostly because drug effect is low, side effect is big and unsalable, so, study a kind of safely and effectively improvement obesity, the medicines for the treatment of diabetes
Thing or compound are still what pole was necessary.
PAQG is a kind of new drop oleanolic acid type saponin small molecule, is extracted from yellow Populus deltoides.Yellow Populus deltoides is Rubiaceae
Single platymiscium in yellow Populus deltoides category, is grown on southwest China extensively, Vietnam, the ground such as India.At present, this class compound is only
Kind more than 20 is isolated, PAQG is exactly one kind therein.Moreover, the activity research of these compounds is also fewer.It is of the invention first
The secondary regulating and controlling effect for being found that PAQG to lipid metaboli in 3T3-L1 cells.
The content of the invention：
It is an object of the invention to provide it is a kind of have significantly inhibit 3T3-L1 cell differentiations and the compound of accumulation of fat
PAQG, and the compound is in terms of the medicine, food and the health products that improve fat and fat correlated metabolism diseases are prepared
Using.
In order to realize the above-mentioned purpose of the present invention, the invention provides following technical scheme：
Applications of the compound PAQG in the inhibitor broken up to 3T3-L1 PECTORAL LIMB SKELETONs is prepared,
Applications of the compound PAQG in the conditioning agent to mature fat cell fat metabolism is prepared.
Applications of the compound PAQG in slimming medicine is prepared.
Applications of the compound PAQG in the medicine for preparing regulation blood fat.
Prepared according to applications of the described compound PAQG in slimming medicine is prepared, and described compound PAQG
The application in the medicine of blood fat is adjusted, wherein PAQG is broken up by significantly inhibiting 3T3-L1 PECTORAL LIMB SKELETONs, lowers differentiation phase
Transcription factor and albumen PPAR γ, C/EBP β, C/EBP α and FABP4 expression and the release of adiponectin are closed, and by suppressing
Aliphatic acid synthesizes and promotes lipid oxidation to suppress the accumulation of fat in fat cell, reaches fat-reducing and regulating blood lipid action.
The present invention additionally provides compound PAQG and is preparing improvement obesity and treating or preventing fat correlated metabolism simultaneously
Application in the medicine of disease.
Preparing improvement obesity according to described compound PAQG and treating or preventing the medicines of fat correlated metabolism diseases
Application in thing, wherein PAQG be by significantly inhibit 3T3-L1 PECTORAL LIMB SKELETONs break up, lower differentiation associated transcription factor and
Albumen PPAR γ, C/EBP β, C/EBP α and FABP4 expression and the release of adiponectin, and by suppress aliphatic acid synthesis and
Promote lipid oxidation to suppress the accumulation of fat in fat cell, reach antiobesity action.
The present invention still further provides compound PAQG and prepare the food of the fat and fat correlated metabolism diseases of improvement
And the application in health products.
By a large amount of multiple independent repeated trials, regulation and control of the PAQG to lipid metaboli in 3T3-L1 cells are found that first
Effect.Present invention discover that PAQG can significantly inhibit the differentiation of 3T3-L1 PECTORAL LIMB SKELETONs, differentiation associated transcription factor and egg are lowered
The expression of (PPAR γ, C/EBP β, C/EBP α and FABP4) and the release of adiponectin in vain.Meanwhile, synthesized by suppressing aliphatic acid
Suppress the accumulation of fat in fat cell with promotion lipid oxidation.Its effect for adjusting lipid metaboli may be with AMPK signal paths
Activation is relevant.Under safely and effectively dosage, PAQG improves in terms of adipocyte count and fat content size two
It is fat.
Brief description of the drawings
Fig. 1 oil red O stains.3T3-L1 PECTORAL LIMB SKELETONs induction differentiation 6 days.Experimental group adds the PAQG of various concentrations；
Con groups are not added with compound, are substituted with 0.1%DMSO；Undifferentiated groups are used as blank control without induction agent.
Experiment is independent in triplicate.
Fig. 2 .3T3-L1 PECTORAL LIMB SKELETONs induction differentiation 6 days, experimental group adds the PAQG of various concentrations, being not added with of control group
Compound, is substituted with 0.1%DMSO.(A) differentiation associated transcription factor (PPAR γ, C/EBP β and C/EBP α) and albumen FABP4
Electrophoresis result；(B) the adiponectin emission levels in culture medium.Experiment is independently compared in triplicate, between group uses independent sample t
Examine, error line is standard error.Compared with control group, * P<0.05,**P<0.01.
The fat cell that Fig. 3 differentiation is completed, is handled 48 hours, 0.1%DMSO is compared with various concentrations PAQG.(A),
Upper figure, medication；Figure below, after being administered 48 hours, fat drips content in fat cell；(B), under normal circumstances, 3T3-L1 fat
The time-concentration curve of triglycerides in cell；(C), administration processing after, in 3T3-L1 fat cells triglycerides when
M- concentration curve；(D), after administration processing, the time-concentration curve of the free fatty in 3T3-L1 fat cells；(E), give
After medicine processing, the time-concentration curve of the glycerine in 3T3-L1 fat cells；(F), glycerine release in 3T3-L1 fat cells
Time-concentration curve.Experiment is independently compared in triplicate, between group uses independent samples t test, and error line is standard error.With it is right
Compare according to group, * P<0.05,**P<0.01.
Fig. 4 (A), 3T3-L1 PECTORAL LIMB SKELETONs break up in the inductive differentiation medium containing various concentrations PAQG, 6 days
Afterwards, the albumin A MPK and p-AMPK that are detected with polyacrylamide gel electrophoresis expression；(B), to the amount of (A) experimental result
Change；(C), the overall process of differentiation is induced to add 20 μM of PAQG, the DMSO of control group addition 0.1% in 3T3-L1 PECTORAL LIMB SKELETONs,
Then the expression that protein sample detects AMPK and p-AMPK is collected at different time points；(D), to (C) experimental result
Quantify (arrow represents that compound PAQG starts administration processing).Experiment is independently compared in triplicate, between group to be examined using independent sample t
Test, error line is standard error.Compared with control group, * P<0.05,**P<0.01.
Fig. 5 by the PAQG of the 3T3-L1 fat cell various concentrations broken up be incubated 48 hours (collect protein sample and
RT-PCR samples).(A), p-AMPK and AMPK electrophoresis result；(B), to the quantization of (A) protein electrophoresis result；(C), RT-PCR
As a result：The expression of the gene (SREBP1c, ACC α, SCD1, FAS) related to aliphatic acid synthesis regulated and controled by AMPK；(D), RT-
PCR results：The expression of the gene (PDK4, CPT1a, ACOX1) related to lipid oxidation regulated and controled by AMPK.Experiment is independent to repeat three
It is secondary, compare between group and use independent samples t test, error line is standard error.Compared with control group, * P<0.05,**P<0.01.
Fig. 6 are in 3T3-L1 cells, compound PAQG cytotoxicity experiment.Experiment is independent in triplicate.
Embodiment：
Below in conjunction with the accompanying drawings, further illustrated with embodiments of the invention the present invention essentiality content, but not with
This limits the present invention.
Embodiment 1：
The compounds of this invention PAQG, shown in structural formula such as following formula (I), is extracted from yellow Populus deltoides, by the double versions in Chinese Academy of Sciences west
Receive tropical plants garden offer, preparation method refer in following document described method.
ZHANG Y,TAN N,HUANG H,et al.Triterpenoid Saponins from Metadina
trichotoma[J].Zeitschrift für Naturforschung B,2007,62(5):745‐748.
1st, PAQG suppresses the differentiation of 3T3-L1 PECTORAL LIMB SKELETONs：
Hungry two days of 3T3-L1 PECTORAL LIMB SKELETONs, with induction agent induction differentiation three days, then with maintenance medium culture one
My god, fresh culture is changed afterwards, and normally culture is divided into fat cell.According to the experimental method, in whole atomization
With the PAQG processing of various concentrations (0,2.5 μM, 5 μM, 10 μM, 20 μM), control group is substituted with 0.1% DMSO.Treat that cell is complete
After full differentiation is good, the fat content in fat cell is detected with the method for oil red O stain.As shown in figure 1, pair with normal differentiation
Compared according to a group cell, the differentiation of administration group fat cell is substantially suppressed, and be presented concentration gradient dependence, and 20 μM
PAQG is up to 90% to the suppression level of Adipocyte Differentiation, and fat drips are not observed substantially in cell now.
Fig. 1 oil red O stains.3T3-L1 PECTORAL LIMB SKELETONs induction differentiation 6 days.Experimental group adds the PAQG of various concentrations；
Con groups are not added with compound, are substituted with 0.1%DMSO；Undifferentiated groups are used as blank control without induction agent.
Experiment is independent in triplicate.
Fig. 2 .3T3-L1 PECTORAL LIMB SKELETONs induction differentiation 6 days, experimental group adds the PAQG of various concentrations, being not added with of control group
Compound, is substituted with 0.1%DMSO.(A) differentiation associated transcription factor (PPAR γ, C/EBP β and C/EBP α) and albumen FABP4
Electrophoresis result；(B) the adiponectin emission levels in culture medium.Experiment is independently compared in triplicate, between group uses independent sample t
Examine, error line is standard error.Compared with control group, * P<0.05,**P<0.01.
Meanwhile, the present invention collects the protein sample of experiment above, is detected with agarose gel electrophoresis method, it is found that differentiation is related
The expression of transcription factor and albumen (PPAR γ, C/EBP β, C/EBP α and FABP4) is remarkably decreased (Fig. 2A), also, uses adiponectin
The release that kit detects adiponectin in culture medium is also reduced as shown in Figure 2 B.Result in terms of three above proves PAQG
Significantly inhibit the differentiation of 3T3-L1 PECTORAL LIMB SKELETONs.
2nd, PAQG suppresses the accumulation of fat in mature fat cell
After 3T3-L1 PECTORAL LIMB SKELETON normal differentiations terminate, handled 48 hours with 10 μM and 20 μM of PAQG respectively, control group
For 0.1%DMSO (such as on Fig. 3 A).As shown in Figure 3A, compared with cellular control unit, experimental group is thin for observation result under the microscope
Fat content in born of the same parents is significantly reduced.Meanwhile, we are dissolved with absolute ethyl alcohol and collect the fat in cell, and detect wherein glycerine three
The content of ester (TG).As shown in Figure 3 B, consistent with microscopy result, intracellular TG contents are significantly reduced after PAQG processing, in concentration ladder
Spend dependence.After cell without doing administration processing, normal differentiation, the TG of intracellular is (Fig. 3 B) constantly accumulated.PAQG causes
TG is reduced in fat cell, and the TG hydrolysis in fat cell, generation free fatty (FFA) and glycerine may be promoted due to it
(Glycerol), it is discharged into culture medium.Therefore, we have detected the content of FFA and Glycerol in culture medium with kit, such as
Shown in Fig. 3 D and 3E, FFA the and Glycerol contents in culture medium all dramatically increase (compared with Normal group), and are also in
Concentration gradient dependence.
In order to which in dynamic detection PAQG processing procedures, the fat content in fat cell changes.We are in PAQG processing
In 48 hours, the glycerol content (Fig. 3 F) in detection different time points culture medium, and the time for depicting glycerine release with this is bent
Line.As a result show, in control group and experimental group, the content of glycerine is all to increase as time went on and gradually, but chemical combination
After thing processing, the content of glycerine is in concentration gradient dependence apparently higher than control group.The result is pointed out, PAQG lipid-loweringing
Effect is relevant with promoting TG degradeds in fat cell.
The fat cell that Fig. 3 differentiation is completed, is handled 48 hours, 0.1%DMSO is compared with various concentrations PAQG.(A),
Upper figure, medication；Figure below, after being administered 48 hours, fat drips content in fat cell；(B), under normal circumstances, 3T3-L1 fat
The time-concentration curve of triglycerides in cell；(C), administration processing after, in 3T3-L1 fat cells triglycerides when
M- concentration curve；(D), after administration processing, the time-concentration curve of the free fatty in 3T3-L1 fat cells；(E), give
After medicine processing, the time-concentration curve of the glycerine in 3T3-L1 fat cells；(F), glycerine release in 3T3-L1 fat cells
Time-concentration curve.Experiment is independently compared in triplicate, between group uses independent samples t test, and error line is standard error.With it is right
Compare according to group, * P<0.05,**P<0.01.
3rd, PAQG activates AMPK signal paths in 3T3-L1 cells
When observing that PAQG suppresses 3T3-L1 PECTORAL LIMB SKELETON differentiating phenomenons, we collect the protein sample, and
AMPK and p-AMPK protein expression is detected with agarose gel electrophoresis method.As illustrated in figures 4 a and 4b, AMPK phosphorylation level
As gradient increase is presented in PAQG change in concentration.In order to further probe into AMPK in 3T3-L1 PECTORAL LIMB SKELETON atomizations
The situation of change of phosphorylation, We conducted following experiment.It is administered when differentiation is induced just, control group uses 0.1%
DMSO is substituted, and in day1, day3, day4, day6, these different times check and accept albumen, detects AMPK and p-AMPK expression.
As a result as shown in figures 4 c and 4d, PAQG can sustained activation AMPK during the entire process of the differentiation of 3T3-L1 PECTORAL LIMB SKELETONs
Phosphorylation.
In order to probe into the mechanism of action that PAQG suppresses the accumulation of 3T3-L1 cellular fats, We conducted following experiment：When thin
After born of the same parents' differentiation terminates, cell is handled with 10 μM and 20 μM of PAQG respectively, control is used as with 0.1%DMSO.Two days later, it is a part of
Collect the expression that protein sample detects AMPK and p-AMPK；Another part collect RNA sample detection AMPK signal paths downstream with
The related gene expression of lipid metaboli.Wherein, the AMPK signal paths gene related to lipid metaboli mainly include aliphatic acid synthesis and
The class of lipid oxidation two.And the gene related to aliphatic acid synthesis mainly has：SREBP1c、ACCα、SCD1、FAS；It is related to lipid oxidation
Gene mainly have：PDK4、CPT1a、ACOX1.As shown in figures 5 a-d, AMPK phosphorylation level is with PAQG's for experimental result
Gradient increase is presented in change in concentration.In addition, gene SREBP1c, ACC α, SCD1, FAS expression reduction, and PDK4 and CPT1a
Expression increase, ACOX1 expression is basically unchanged.Thus illustrate, PAQG may suppress fat by activating AMPK signal paths
Acid synthesizes and promotes lipid oxidation, so as to play effect for reducing fat.
Fig. 4 .A), 3T3-L1 PECTORAL LIMB SKELETONs break up in the inductive differentiation medium containing various concentrations PAQG, 6 days
Afterwards, the albumin A MPK and p-AMPK that are detected with polyacrylamide gel electrophoresis expression；(B), to the amount of (A) experimental result
Change；(C), the overall process of differentiation is induced to add 20 μM of PAQG, the DMSO of control group addition 0.1% in 3T3-L1 PECTORAL LIMB SKELETONs,
Then the expression that protein sample detects AMPK and p-AMPK is collected at different time points；(D), to (C) experimental result
Quantify (arrow represents that compound PAQG starts administration processing).Experiment is independently compared in triplicate, between group to be examined using independent sample t
Test, error line is standard error.Compared with control group, * P<0.05,**P<0.01.
Fig. 5 by the PAQG of the 3T3-L1 fat cell various concentrations broken up be incubated 48 hours (collect protein sample and
RT-PCR samples).(A), p-AMPK and AMPK electrophoresis result；(B), to the quantization of (A) protein electrophoresis result；(C), RT-PCR
As a result：The expression of the gene (SREBP1c, ACC α, SCD1, FAS) related to aliphatic acid synthesis regulated and controled by AMPK；(D), RT-
PCR results：The expression of the gene (PDK4, CPT1a, ACOX1) related to lipid oxidation regulated and controled by AMPK.Experiment is independent to repeat three
It is secondary, compare between group and use independent samples t test, error line is standard error.Compared with control group, * P<0.05,**P<0.01.
4th, PAQG cytotoxicity experiment
The present invention have detected cytotoxicity experiments (Fig. 6) of the PAQG in mouse 3T3-L1 PECTORAL LIMB SKELETONs.As a result show,
Compound PAQG does not have the compound Cmax used in cytotoxicity, this experimentation to be 20 μM in the range of 0~50 μM,
This concentration is in safe range.
Fig. 6 are in 3T3-L1 cells, compound PAQG cytotoxicity experiment.Experiment is independent in triplicate.
Embodiment 2
By the gained compound PAQG of embodiment 1, compare 1 by compound and excipient weight:1 or 1:2 ratio adds figuration
Agent, pelletizing press sheet.
Embodiment 3：
Compound PAQG is made by embodiment 1, routinely capsule is made in capsule preparations method.
Embodiment 4：
Compound PAQG first is made by embodiment 1, then tablet is made as follows.
Tablet：Compound PAQG100mg, appropriate starch, appropriate corn steep liquor, Magnesium Stearate proper quantity.Preparation method：By chemical combination
Thing is mixed with auxiliary agent, sieving, is uniformly mixed in suitable container, obtained granulating mixture tabletting.
Embodiment 5：
Capsule：Compound PAQG100mg, appropriate starch, Magnesium Stearate proper quantity.
Preparation method：Compound PAQG is mixed with auxiliary agent, sieves, is uniformly mixed in suitable container, what is obtained
Mixture loads hard gelatin capsule.
Embodiment 6：
Tablet：Embodiment 1 gained compound PAQG10mg, lactose 180mg, starch 55mg, magnesium stearate 5mg；
Preparation method：Compound PAQG, newborn sugar and starch are mixed, uniformly moistened with water, the mixture mistake after moistening
Sieve and dry, re-sieving adds magnesium stearate, then by mixture tabletting, every weight 250mg, compounds content is 10mg.
Embodiment 7：
Ampulla：Embodiment 1 gained compound PAQG2mg, sodium chloride 10mg；
Preparation method：Compound PAQG and sodium chloride are dissolved in appropriate water for injection, resulting solution are filtered, in nothing
It is fitted under the conditions of bacterium in ampoule bottle.
Embodiment 8：
Capsule：Embodiment 1 gained compound PAQG10mg, lactose 187mg, magnesium stearate 3mg；
Preparation method：Compound is mixed with auxiliary agent, sieved, obtained mixture is loaded glutoid glue by uniform mixing
Capsule, each capsule weight 200mg, active component content is 10mg.
Embodiment 9：
The preparation of food：
Preparation method：The gained compound PAQG of Example 1 is with 1:7 ratio is added in jam, can increase food
Fragrance, while can also play health-care efficacy.
Embodiment 10：
The preparation of food：
Preparation method：The gained compound PAQG of Example 1 is with 1:8 ratio is added in honey, can increase food
Fragrance, while can also play health-care efficacy.
Embodiment 11：
Sour milk beverage formula (W%) containing compound PAQG：
The above-mentioned beverage of the present invention is made in the method for routinely making food.
Claims (9)
1. applications of the compound PAQG in the inhibitor broken up to 3T3-L1 PECTORAL LIMB SKELETONs is prepared.
2. applications of the compound PAQG in the conditioning agent to mature fat cell fat metabolism is prepared.
3. applications of the compound PAQG in slimming medicine is prepared.
4. applications of the compound PAQG in the medicine for preparing regulation blood fat.
5. applications of the compound PAQG according to claim 3 in slimming medicine is prepared, it is characterised in that PAQG passes through
Significantly inhibit 3T3-L1 PECTORAL LIMB SKELETONs differentiation, lower differentiation associated transcription factor and albumen PPAR γ, C/EBP β, C/EBP α and
FABP4 expression and the release of adiponectin, and by suppressing aliphatic acid synthesis and promoting lipid oxidation to suppress in fat cell
Accumulation of fat, reach fat-reducing and regulating blood lipid action.
6. applications of the compound PAQG according to claim 4 in the medicine for preparing regulation blood fat, it is characterised in that
PAQG is broken up by significantly inhibiting 3T3-L1 PECTORAL LIMB SKELETONs, lowers differentiation associated transcription factor and albumen PPAR γ, C/EBP β,
C/EBP α and FABP4 expression and the release of adiponectin, and by suppressing aliphatic acid synthesis and promoting lipid oxidation to suppress fat
Accumulation of fat in fat cell, reaches fat-reducing and regulating blood lipid action.
7. compound PAQG is preparing the application in improving medicine that is fat and treating or preventing fat correlated metabolism diseases.
8. compound PAQG according to claim 7 is preparing improvement obesity and is treating or preventing fat correlated metabolism disease
Application in the medicine of disease, it is characterised in that PAQG is broken up by significantly inhibiting 3T3-L1 PECTORAL LIMB SKELETONs, lowers differentiation related
Transcription factor and albumen PPAR γ, C/EBP β, C/EBP α and FABP4 expression and the release of adiponectin, and by suppressing fat
Fat acid synthesizes and promotes lipid oxidation to suppress the accumulation of fat in fat cell, reaches antiobesity action.
9. compound PAQG is preparing the application in improving the food and health products of fat and fat correlated metabolism diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710265740.1A CN106994131B (en) | 2017-04-21 | 2017-04-21 | A kind of application adjusting lipid metaboli and fat compound PAQG in pharmacy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710265740.1A CN106994131B (en) | 2017-04-21 | 2017-04-21 | A kind of application adjusting lipid metaboli and fat compound PAQG in pharmacy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106994131A true CN106994131A (en) | 2017-08-01 |
| CN106994131B CN106994131B (en) | 2019-12-03 |
Family
ID=59434441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710265740.1A Expired - Fee Related CN106994131B (en) | 2017-04-21 | 2017-04-21 | A kind of application adjusting lipid metaboli and fat compound PAQG in pharmacy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106994131B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108610409A (en) * | 2018-04-09 | 2018-10-02 | 深圳大学 | ETV5 is preparing the application in preventing or treating obesity and correlated metabolism diseases drug |
| CN109010800A (en) * | 2018-07-05 | 2018-12-18 | 中国科学院深圳先进技术研究院 | PDGF-BB is inhibiting Adipocyte Differentiation, formation and its application of function |
| CN109722421A (en) * | 2018-12-14 | 2019-05-07 | 南京市妇幼保健院 | A kind of fat cell endogenous polypeptide and its application |
| CN110272997A (en) * | 2018-03-14 | 2019-09-24 | 武汉凯德维斯生物技术有限公司 | A kind of purposes of C/EBP β gene or albumen |
| CN110974821A (en) * | 2019-12-24 | 2020-04-10 | 浙江大学 | Application of Eurycomanone and analogues thereof in preparation of medicines for treating hyperlipidemia and fatty liver or weight-reducing products |
| WO2022033163A1 (en) * | 2020-08-14 | 2022-02-17 | 武汉大学 | Molecular marker related to aging and healthy aging and application thereof in improving healthy aging |
| CN114931577A (en) * | 2022-06-21 | 2022-08-23 | 上海市同仁医院 | Application of indole-3-acrylic acid in inhibiting differentiation of white adipose precursor cells |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102286057A (en) * | 2011-07-07 | 2011-12-21 | 北华大学 | Oleanane-type triterpenoid compounds and preparation method and medicinal use thereof |
| CN105147710A (en) * | 2015-09-11 | 2015-12-16 | 中国科学院西双版纳热带植物园 | Hypoglycemic agent as well as preparation method and application thereof |
-
2017
- 2017-04-21 CN CN201710265740.1A patent/CN106994131B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102286057A (en) * | 2011-07-07 | 2011-12-21 | 北华大学 | Oleanane-type triterpenoid compounds and preparation method and medicinal use thereof |
| CN105147710A (en) * | 2015-09-11 | 2015-12-16 | 中国科学院西双版纳热带植物园 | Hypoglycemic agent as well as preparation method and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| YU-MEI ZHANG等: "Triterpenoid Saponins from Metadina trichotoma", 《Z. NATURFORSCH》 * |
| 张明发等: "齐墩果酸和熊果酸的神经精神药理作用研究进展", 《药物评价研究》 * |
| 张明发等: "齐墩果酸和熊果酸调血脂、抗肥胖药理作用研究进展", 《药物评价研究》 * |
| 张玉梅等: "黄棉木中两个新的三萜类化合物", 《云南植物研究》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110272997A (en) * | 2018-03-14 | 2019-09-24 | 武汉凯德维斯生物技术有限公司 | A kind of purposes of C/EBP β gene or albumen |
| CN110272997B (en) * | 2018-03-14 | 2023-04-28 | 华中科技大学同济医学院附属同济医院 | Application of C/EBP beta gene or protein |
| CN108610409A (en) * | 2018-04-09 | 2018-10-02 | 深圳大学 | ETV5 is preparing the application in preventing or treating obesity and correlated metabolism diseases drug |
| CN109010800A (en) * | 2018-07-05 | 2018-12-18 | 中国科学院深圳先进技术研究院 | PDGF-BB is inhibiting Adipocyte Differentiation, formation and its application of function |
| CN109722421A (en) * | 2018-12-14 | 2019-05-07 | 南京市妇幼保健院 | A kind of fat cell endogenous polypeptide and its application |
| CN110974821A (en) * | 2019-12-24 | 2020-04-10 | 浙江大学 | Application of Eurycomanone and analogues thereof in preparation of medicines for treating hyperlipidemia and fatty liver or weight-reducing products |
| WO2022033163A1 (en) * | 2020-08-14 | 2022-02-17 | 武汉大学 | Molecular marker related to aging and healthy aging and application thereof in improving healthy aging |
| CN114931577A (en) * | 2022-06-21 | 2022-08-23 | 上海市同仁医院 | Application of indole-3-acrylic acid in inhibiting differentiation of white adipose precursor cells |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106994131B (en) | 2019-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106994131B (en) | A kind of application adjusting lipid metaboli and fat compound PAQG in pharmacy | |
| WO2015172608A1 (en) | Capsule for assisting in reducing blood fat and preparation method therefor | |
| CN102907677A (en) | Sea-buckthorn perilla seed oil soft capsule having function of assisting blood-fat reduction and preparation method thereof | |
| CN104800269B (en) | A kind of Chinese medicine external emulsifiable paste for treating psoriasis and preparation method thereof | |
| CN114632101B (en) | Cordyceps guangdongensis weight-losing lipid-lowering liver-protecting compound and preparation method and application thereof | |
| CN105944088A (en) | Composition for regulating ovarian function and application of composition | |
| Rohdewald | Update on the clinical pharmacology of Pycnogenol (R) | |
| CN103494206B (en) | Preparation process of soft capsule containing peony seed essential oil and peony petal isoflavone | |
| CN108567955A (en) | A kind of pharmaceutical composition and preparation method thereof of prevention diabetic nephropathy | |
| WO2015190872A1 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for treating and preventing obesity | |
| CN105012826B (en) | A kind of intelligence development leaf extract and preparation method thereof, application | |
| CN101234160A (en) | Fat-reducing and liver-protecting Chinese medicine preparation and preparation thereof | |
| JP6701583B2 (en) | Composition for treating type 1 diabetes mellitus | |
| CN103766901A (en) | Application of andrographolide C to preparation of weight-losing food or medicine | |
| CN100402052C (en) | Blood fat-reducing medicine and its preparation method | |
| CN108926595A (en) | A kind of health care product with protection liver and hypolipemic function | |
| WO2016141774A1 (en) | Uses of jilin ginseng oligopeptide in preparing food product or healthcare food product for improving and enhancing sexual function | |
| CN102106534A (en) | Composition for assisting in lowering blood fat and preparation method thereof | |
| WO2019100843A1 (en) | Enteromorpha prolifera polysaccharide composite blood lipid-lowering health care product and preparation method therefor | |
| CN105560308B (en) | Flower of JINHUAKUI is preparing the application in the product for preventing and treating prostatic disorders | |
| JP2019532039A (en) | Composition comprising pollen and / or pistil extract, method of preparation and related uses | |
| CN107540643A (en) | Ganoderma lucidum composition GL 1 and as estrogen replacement in terms of application | |
| CN1850202A (en) | Vagina external-use medicine composition and its preparing method and use | |
| JP5548379B2 (en) | Antihistamine containing pollen cargo | |
| CN110327323A (en) | Application of the Cichoric acid in preparation treatment obesity or its complication medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191203 |